Evidence map›Paper›PMID 24533282›Full record

ReviewInternational journal for parasitology. Drugs and drug resistance2012

Current treatment options for Dientamoeba fragilis infections.

Noriyuki Nagata, Deborah Marriott, John Harkness, John T Ellis, Damien Stark

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal for parasitology. Drugs and drug resistance, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.2field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 46 citations in OpenAlex.

  1. Review
  2. Journal of medical microbiology · 2026
    Review
  3. Identification of four novelInternational journal of systematic and evolutionary microbiology · 2025
    Article
  4. Treatment ofNew microbes and new infections · 2023
    Article
  5. Article
  6. Article
  7. Article
  8. Paromomycin is superior to metronidazole in Dientamoeba fragilis treatment.International journal for parasitology. Drugs and drug resistance · 2019
    Article
  9. Clinical and Epidemiological Characteristics of Patients withThe American journal of tropical medicine and hygiene · 2018
    Observational
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Noriyuki NagataDivision of Microbiology, SydPath, St. Vincent's Hospital, Darlinghurst, Australia ; University of Technology Sydney, School of Medical and Molecular Biosciences, Broadway, Australia.
Deborah MarriottDivision of Microbiology, SydPath, St. Vincent's Hospital, Darlinghurst, Australia ; University of Technology Sydney, School of Medical and Molecular Biosciences, Broadway, Australia.
John HarknessDivision of Microbiology, SydPath, St. Vincent's Hospital, Darlinghurst, Australia ; University of Technology Sydney, School of Medical and Molecular Biosciences, Broadway, Australia.
John T EllisUniversity of Technology Sydney, School of Medical and Molecular Biosciences, Broadway, Australia ; University of Technology Sydney, iThree Institute, Broadway, Australia.
Damien StarkDivision of Microbiology, SydPath, St. Vincent's Hospital, Darlinghurst, Australia ; University of Technology Sydney, School of Medical and Molecular Biosciences, Broadway, Australia.
University of Technology Sydney · AUSt Vincent's Hospital Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dientamoeba fragilis belongs to the trichomonad group of protozoan parasites and it has been implicated as a cause of gastrointestinal disease with world-wide prevalences ranging from 0.5% to 16%. The majority of patients with dientamoebiasis present with gastrointestinal complaints. Chronic symptoms are common with up to a third of patients exhibiting persistent diarrhoea. Numerous studies have successfully demonstrated parasite clearance, coupled with complete resolution of clinical symptoms following treatment with various antiparasitic compounds. Treatments reported to be successful for dientamoebiasis include carbarsone, diphetarsone, tetracyclines, paromomycin, erythromycin, hydroxyquinolines and the 5-nitroimidazoles, including metronidazole, secnidazole, tinidazole and ornidazole. It is of note that most current treatment data is based only on small number of case reports. No large scale double blind randomised placebo controlled trials testing the efficacy of antimicrobial agents against D. fragilis has been undertaken highlighting the need for further study. In addition there is very little in vitro susceptibility data available for the organism making some current treatment options questionable. The aim of this review is to critically discuss all treatment options currently available for dientamoebiasis.

Indexed as

Dientamoeba fragilisDrug Clinical efficacyTherapy

Identifiers

PMID24533282
PMCPMC3862407
OpenAlexW2022051683

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.